Natalie Jayaram1, John A Spertus2, Michael L O'Byrne3, Paul S Chan4, Kevin F Kennedy5, Lisa Bergersen6, Andrew C Glatz7. 1. Children's Mercy Hospitals and Clinics, Kansas City, MO. Electronic address: njayaram@cmh.edu. 2. Saint Luke's Mid America Heart Institute/UMKC, Kansas City, MO. Electronic address: spertusj@umkc.edu. 3. Children's National Medical Center, Washington, DC; George Washington University School of Medicine, Washington, DC. Electronic address: MLOBYRNE@childrensnational.org. 4. Saint Luke's Mid America Heart Institute/UMKC, Kansas City, MO. Electronic address: paulchan.mahi@gmail.com. 5. Saint Luke's Mid America Heart Institute/UMKC, Kansas City, MO. Electronic address: kfkennedy@saint-lukes.org. 6. Boston Children's Hospital, Boston, MA. Electronic address: Lisa.Bergersen@CARDIO.CHBOSTON.ORG. 7. The Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: GLATZ@email.chop.edu.
Abstract
BACKGROUND: The association between institutional volume and outcomes has been demonstrated for cardiac catheterization among adults, but less is known about this relationship for patients with congenital heart disease (CHD) undergoing cardiac catheterization. METHODS: Within the IMPACT registry, we identified all catheterizations between January 2011 and March 2015. Hierarchical logistic regression, adjusted for patient and procedural characteristics, was used to determine the association between annual catheterization lab volume and occurrence of a major adverse event (MAE). RESULTS: Of 56,453 catheterizations at 77 hospitals, an MAE occurred in 1014 (1.8%) of cases. In unadjusted analysis, a MAE occurred in 2.8% (123/4460) of cases at low-volume hospitals (<150 procedures annually), as compared with 1.5% (198/12,787), 2.0% (431/21,391), and 1.5% (262/17,815) of cases at medium- (150-299 annual procedures), high- (300-499 annual procedures), and very-high-volume (≥500 procedures annually) hospitals, respectively, P<.001. After multivariable adjustment, this significant relationship between annual procedure volume and occurrence of an MAE persisted. Compared to low-volume programs, the odds of an MAE was 0.55 (95% CI 0.35-0.86, P=.008), 0.62 (95% CI 0.41-0.95, P=.03), and 0.52 (95% CI 0.31-0.90, P=.02) at medium-, high-, and very-high-volume programs, respectively. CONCLUSIONS: Although the risk of MAE after cardiac catheterization in patients with CHD is low at all hospitals, it is higher among hospitals with fewer than 150 cases annually. These results support the notion that centers meeting this threshold volume for congenital cardiac catheterizations may achieve improved patient outcomes.
BACKGROUND: The association between institutional volume and outcomes has been demonstrated for cardiac catheterization among adults, but less is known about this relationship for patients with congenital heart disease (CHD) undergoing cardiac catheterization. METHODS: Within the IMPACT registry, we identified all catheterizations between January 2011 and March 2015. Hierarchical logistic regression, adjusted for patient and procedural characteristics, was used to determine the association between annual catheterization lab volume and occurrence of a major adverse event (MAE). RESULTS: Of 56,453 catheterizations at 77 hospitals, an MAE occurred in 1014 (1.8%) of cases. In unadjusted analysis, a MAE occurred in 2.8% (123/4460) of cases at low-volume hospitals (<150 procedures annually), as compared with 1.5% (198/12,787), 2.0% (431/21,391), and 1.5% (262/17,815) of cases at medium- (150-299 annual procedures), high- (300-499 annual procedures), and very-high-volume (≥500 procedures annually) hospitals, respectively, P<.001. After multivariable adjustment, this significant relationship between annual procedure volume and occurrence of an MAE persisted. Compared to low-volume programs, the odds of an MAE was 0.55 (95% CI 0.35-0.86, P=.008), 0.62 (95% CI 0.41-0.95, P=.03), and 0.52 (95% CI 0.31-0.90, P=.02) at medium-, high-, and very-high-volume programs, respectively. CONCLUSIONS: Although the risk of MAE after cardiac catheterization in patients with CHD is low at all hospitals, it is higher among hospitals with fewer than 150 cases annually. These results support the notion that centers meeting this threshold volume for congenital cardiac catheterizations may achieve improved patient outcomes.
Authors: Lisa Bergersen; Kimberlee Gauvreau; Susan R Foerster; Audrey C Marshall; Doff B McElhinney; Robert H Beekman; Russel Hirsch; Jacqueline Kreutzer; David Balzer; Julie Vincent; William E Hellenbrand; Ralf Holzer; John P Cheatham; John W Moore; Grant Burch; Laurie Armsby; James E Lock; Kathy J Jenkins Journal: JACC Cardiovasc Interv Date: 2011-09 Impact factor: 11.195
Authors: Thomas M Bashore; Stephen Balter; Ana Barac; John G Byrne; Jeffrey J Cavendish; Charles E Chambers; James Bernard Hermiller; Scott Kinlay; Joel S Landzberg; Warren K Laskey; Charles R McKay; Julie M Miller; David J Moliterno; John W M Moore; Sandra M Oliver-McNeil; Jeffrey J Popma; Carl L Tommaso Journal: J Am Coll Cardiol Date: 2012-05-08 Impact factor: 24.094
Authors: Tara Karamlou; Marshall L Jacobs; Sara Pasquali; Xia He; Kevin Hill; Sean O'Brien; David Michael McMullan; Jeffrey P Jacobs Journal: Ann Thorac Surg Date: 2014-07-25 Impact factor: 4.330
Authors: Laurie B Armsby; Robert N Vincent; Susan R Foerster; Ralf J Holzer; John W Moore; Audrey C Marshall; Larry Latson; Michael Brook Journal: J Am Coll Cardiol Date: 2015-03-13 Impact factor: 24.094
Authors: Carl H Backes; Lisa Bergersen; Jonathan J Rome; Sarosh P Batlivala; Andrew C Glatz; Bugsu Ovunc; Sthuthi David; Brian K Rivera; Urbee Haque; Kevin Kollins; Han Yin; Ralf J Holzer Journal: Catheter Cardiovasc Interv Date: 2014-10-07 Impact factor: 2.692
Authors: James V Freeman; Yongfei Wang; Jeptha P Curtis; Paul A Heidenreich; Mark A Hlatky Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: P D McGrath; D E Wennberg; J D Dickens; A E Siewers; F L Lucas; D J Malenka; M A Kellett; T J Ryan Journal: JAMA Date: 2000-12-27 Impact factor: 56.272
Authors: Michael L O'Byrne; Marisa E Millenson; James M Steven; Matthew J Gillespie; Yoav Dori; Andrew C Glatz; Jonathan J Rome Journal: JACC Cardiovasc Interv Date: 2019-04-10 Impact factor: 11.195
Authors: Michael L O'Byrne; Kevin F Kennedy; James M Steven; Kevin D Hill; Reid C Chamberlain; Marisa E Millenson; Christopher L Smith; Yoav Dori; Matthew J Gillespie; Jonathan J Rome; Andrew C Glatz Journal: JACC Cardiovasc Interv Date: 2021-02-22 Impact factor: 11.195
Authors: Michael L O'Byrne; Lihai Song; Jing Huang; David J Goldberg; Monique M Gardner; Chitra Ravishankar; Jonathan J Rome; Andrew C Glatz Journal: Pediatr Cardiol Date: 2021-02-02 Impact factor: 1.655
Authors: Michael L O'Byrne; Jennifer A Faerber; Hannah Katcoff; Jing Huang; Jonathan B Edelson; David M Finkelstein; Bethan A Lemley; Christopher M Janson; Catherine M Avitabile; Andrew C Glatz; David J Goldberg Journal: Am Heart J Date: 2021-09-25 Impact factor: 4.749
Authors: Michael L O'Byrne; Kevin F Kennedy; Joshua P Kanter; John T Berger; Andrew C Glatz Journal: J Am Heart Assoc Date: 2018-02-28 Impact factor: 5.501
Authors: Akanksha Thakkar; Stephanie Fuentes-Rojas; Eunice Karanja; Ebun Ebunlomo; Allison Millette; Christine H Lee; Y Serena Shen-Lin; Gary Monteiro; Thomas MacGillivray; C Huie Lin Journal: Curr Cardiol Rep Date: 2018-10-11 Impact factor: 2.931
Authors: Michael L O'Byrne; Andrew C Glatz; Jennifer A Faerber; Roopa Seshadri; Marisa E Millenson; Lanyu Mi; Russell T Shinohara; Yoav Dori; Matthew J Gillespie; Jonathan J Rome; Steven M Kawut; Peter W Groeneveld Journal: J Am Heart Assoc Date: 2019-05-07 Impact factor: 5.501
Authors: Michael L O'Byrne; Kevin F Kennedy; Natalie Jayaram; Lisa J Bergersen; Matthew J Gillespie; Yoav Dori; Jeffrey H Silber; Steven M Kawut; Jonathan J Rome; Andrew C Glatz Journal: J Am Heart Assoc Date: 2019-10-17 Impact factor: 5.501